PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Rang in Aktien #1420
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktienkurs
$37.84
Marktkapitalisierung
$15.65B
Veränderung (1 Tag)
-4.42%
Veränderung (1 Jahr)
149.23%
Land
TW
Handel PharmaEssentia Corporation (6446)

Kategorie

Healthcare
Dividendenhistorie für PharmaEssentia Corporation (6446)
PharmaEssentia Corporation (Aktienkürzel: 6446) zahlte insgesamt 1 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: $0.99
Dividendenrendite (TTM): 0.0012
Dividendenzahlungen für PharmaEssentia Corporation (6446) von 2025 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
Liste aller Dividendenzahlungen
Jahr Dividende ändert
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber